Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.

NCT02748707 is registered in ClinicalTrials.gov with Tata Memorial Hospital as lead sponsor.

NCT NCT02748707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02748707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of COX-2 (Cyclooxygenase-2) and EGFR (Epidermal Growth Factor Receptor) Suppression on Molecular Markers of Angiogenesis and Proliferation in Squamous Cell Carcinoma of Oral Cavity - Prospective Randomized Study.
Lead sponsor
Tata Memorial Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
August 18, 2015
Completion date
April 30, 2023
Enrollment
64 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma of buccal mucosa, head and neck cancers, oral squamous cell carcinoma, tongue cancers